In a groundbreaking new study poised to redefine therapeutic approaches to cell injury and inflammation, researchers have unveiled compelling evidence demonstrating the efficacy of tranexamic acid in mitigating mitochondrial DNA release and curbing the inflammatory cascade following oxygen-glucose deprivation and reperfusion (OGD/R) injury in intestinal epithelial cells. This novel research delineates a hitherto underexplored mechanism whereby tranexamic acid—noted primarily for its antifibrinolytic properties—exerts profound protective effects at the cellular and molecular levels within an in vitro model of Caco-2 cell damage, a widely accepted surrogate for human intestinal epithelium.
The study’s focal point is the pathophysiological phenomenon of OGD/R injury, an in vitro reproduction of ischemia-reperfusion events that critically impair intestinal cell viability and function. OGD/R injury induces mitochondrial perturbations leading to the release of mitochondrial DNA (mtDNA) into the cytosol and extracellular milieu. This mtDNA acts as a potent danger-associated molecular pattern (DAMP), inciting inflammatory signaling pathways that exacerbate cellular damage. By infiltrating this vicious cycle, tranexamic acid emerges as a potent modulator of both mitochondrial stability and inflammation, offering unprecedented implications for therapeutic strategies targeting ischemia-reperfusion injuries in gastrointestinal contexts.
Mitochondria, the energy-producing powerhouses of the cell, serve a dual role as arbiters of apoptosis and coordinators of innate immune responses. Under stress, particularly during ischemic insults with subsequent reperfusion, mitochondrial membranes become permeabilized, releasing intermembrane constituents such as mtDNA into the cytoplasm. This liberation triggers pattern recognition receptors, including Toll-like receptor 9 (TLR9), which in turn activate nuclear factor kappa B (NF-κB) pathways, culminating in the synthesis and secretion of proinflammatory cytokines that perpetuate tissue injury.
Tranexamic acid’s well-documented role in inhibiting fibrinolysis by blocking plasminogen activation has recently been expanded by evidence indicating its capacity to stabilize mitochondrial integrity. The researchers demonstrated that treatment with tranexamic acid during OGD/R insult significantly diminished the release of mtDNA from damaged Caco-2 cells. This reduction in mtDNA release was accompanied by a marked decrease in downstream activation of inflammatory markers such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), underscoring the drug’s capacity to attenuate sterile inflammation triggered by cellular stress.
The research team employed a robust in vitro model using human colorectal adenocarcinoma-derived Caco-2 cells, which differentiate to form tight junctions and microvilli resembling intestinal epithelial cells, thus serving as an invaluable platform to study gastrointestinal pathophysiology. Cells were subjected to OGD to mimic ischemia, followed by reoxygenation and glucose restoration to simulate reperfusion injury. Employing precise molecular assays and fluorescence microscopy, the investigators quantitatively and qualitatively assessed mtDNA release and inflammatory markers in treated versus untreated cohorts, evidencing tranexamic acid’s protective properties.
Beyond merely demonstrating significant reductions in mtDNA release and inflammatory cytokine expression, the study elucidated the potential mechanisms of tranexamic acid’s mitochondrial protection. The drug appears to modulate the mitochondrial permeability transition pore (mPTP), a key channel implicated in mitochondrial swelling and outer membrane rupture during ischemic insults. By inhibiting mPTP opening, tranexamic acid preserves mitochondrial membrane potential, enhances ATP synthesis, and curtails apoptotic signaling pathways, thus fostering cytoprotection within the OGD/R-injured epithelium.
The implications of these findings extend far beyond the gastrointestinal tract, shedding light on a potentially universal protective paradigm applicable to multiple ischemia-reperfusion injury models, including cerebral stroke, myocardial infarction, and acute kidney injury. The research team emphasizes that tranexamic acid’s dual role as both an antifibrinolytic agent and a mitochondrial stabilizer offers an unsurpassed therapeutic versatility, spurring interest in repurposing this clinically accessible drug across diverse pathological domains characterized by ischemia and inflammation.
A particularly intriguing dimension of this study lies in its challenge to conventional perspectives on tranexamic acid, traditionally confined to hemostatic contexts. By unveiling its anti-inflammatory properties mediated through mitochondrial preservation and mtDNA release inhibition, the research expands the pharmacological repertoire of tranexamic acid, sparking a paradigm shift in therapeutic strategies aimed at ameliorating the deleterious sequelae of reperfusion injury.
The researchers caution, however, that despite the compelling in vitro results, translation to clinical settings necessitates further probing through rigorous in vivo studies and randomized controlled trials. Elucidating tranexamic acid’s pharmacokinetics and mitochondrial-targeted mechanisms within live organisms will be pivotal for harnessing its full therapeutic potential. Moreover, understanding the optimal dosing regimens, potential off-target effects, and long-term safety profiles represents vital next steps in the drug’s repurposing journey.
At a cellular signaling level, this study intersects with burgeoning research into the cGAS-STING axis, which senses cytosolic DNA, including mtDNA, initiating interferon-related inflammatory cascades. While the current study centered on TLR9-mediated pathways, future investigations could explore tranexamic acid’s effects on these parallel signaling mechanisms, potentially revealing a broader anti-inflammatory spectrum and offering synergistic therapeutic opportunities.
The burgeoning field of mitochondrial medicine stands at the forefront of this research advancement, highlighting mitochondria not merely as metabolic centers but as critical culprits and targets in cell injury and inflammation. This study places tranexamic acid within this transformative context, positioning it as a novel mitochondrial protector with the capacity to mitigate inflammatory injury via modulation of DAMP release and receptor signaling.
These revelations bear consequential significance for patients suffering from intestinal ischemic conditions such as mesenteric ischemia, inflammatory bowel disease exacerbations, and gastrointestinal graft-versus-host disease, where OGD/R insult and resultant inflammatory vicious circles drive morbidity. Integrating tranexamic acid into therapeutic protocols could ameliorate epithelial barrier dysfunction, reduce systemic inflammation, and potentially improve clinical outcomes in these challenging scenarios.
In summary, this pioneering research unpacks a previously unrecognized dimension of tranexamic acid’s pharmacodynamics, demonstrating its capacity to inhibit mtDNA release and suppress inflammatory responses in an OGD/R-induced in vitro injury model of human intestinal epithelial cells. The strategic targeting of mitochondrial distress and DAMP-mediated inflammation heralds a novel therapeutic avenue with extensive cross-disciplinary applications spanning gastroenterology, neurology, cardiology, and critical care medicine.
As the scientific community digests these insights, the emphasis on mitochondria as therapeutic targets continues to gain momentum. Tranexamic acid’s repositioning offers a compelling testament to the untapped potential residing within established drugs when explored through innovative mechanistic lenses. The convergence of mitochondrial biology, inflammation research, and pharmacology embodied by this study holds promise for future breakthroughs in managing ischemia-reperfusion injury and beyond.
This revelation affirms the centrality of mitochondrial health in maintaining cellular resilience and underscores the importance of anti-inflammatory interventions that extend beyond symptomatic relief to address root causes of cellular demise. Tranexamic acid thus emerges not only as a hemostatic agent but as a molecular sentinel guarding against inflammatory destruction when the cells endure ischemic stress.
Given the global burden of ischemia-associated diseases, these findings propel tranexamic acid into the spotlight as a versatile and promising candidate in the arsenal against mitochondrial and inflammatory dysfunction. The continued exploration of its mechanisms and therapeutic boundaries will undeniably enrich the evolving landscape of molecular medicine and patient care.
Subject of Research: Tranexamic acid’s role in inhibiting mitochondrial DNA release and reducing inflammation in an OGD/R-induced cell injury model.
Article Title: Tranexamic acid inhibits mitochondrial DNA release and reduces inflammatory response in an in vitro model of OGD/R-induced Caco-2 cell injury.
Article References:
Wang, Z., Huo, L., Liu, H. et al. Tranexamic acid inhibits mitochondrial DNA release and reduces inflammatory response in an in vitro model of OGD/R-induced Caco-2 cell injury. BMC Pharmacol Toxicol (2026). https://doi.org/10.1186/s40360-026-01160-w
Image Credits: AI Generated
